- The Daily Rip by Stocktwits
- Posts
- Stocktwits Top 25 - Week 10 š
Stocktwits Top 25 - Week 10 š
Our updated list of the market's top stocks.
OVERVIEW
Stocktwits Top 25 - Week 10
Welcome to the Stocktwits Top 25 Newsletter for Week 10 of 2024!
The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time.
Here are the Stocktwits Top 25 Lists for Week 10:
P.S. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!
S&P 500
ST Top 25 S&P 500
The S&P 500 Top 25 list (+1.31%) outperformed the S&P 500 index (-0.26%).
There were 6 major changes to the list this week.
Check out how the momentum meter has performed vs. the S&P 500 index this year:
STOCKTWITS EDGE
Elevate Your Trading Game š
Unleash your trading potential with our new Edge subscription planāfeaturing unique social data, an ad-free experience, and more!
NASDAQ 100
The Large-Cap Nasdaq 100
The Nasdaq 100 Top 25 list (+0.33%) outperformed the Nasdaq 100 index (-1.55%).
There were 3 major changes to the list this week.
RUSSELL 2000
The Growth-Centric Russell 2000
The Russell 2000 Top 25 list (+3.78%) outperformed the Russell 2000 index (-0.30%).
There were 5 major changes to the list this week.
Top Dawg Of The Week š¶
The Top 25 lists' Top Dawg was Apogee Therapeutics, which rallied 81.36%. š
The mid-cap biotech stock surged this week after unveiling promising results for its experimental eczema treatment. Early-stage results show Apogeeās āunder-the-skinā injection approach kept the drug in participantsā systems for roughly three months. š
The company originally aimed for at least 33 days, but these results suggest patients could eventually control their eczema with shots every three to six months, a major differentiator for the drug.
However, some concerns remain as itās facing significant competition in the eczema treatment space, going up against Eli Lillyās drug, Lebrikizumab. Still, Apogeeās management says its drug could be 30% to 40% more powerful. š¤
Time will tell, but for now, the stock is trading at all-time highs. š
$APGE is up 141.73% YTD.
Get In Touch
Have feedback on The Daily Rip? Shoot me (Tom Bruni) an email at [email protected]; Iād love to hear from you.
Want to sponsor this newsletter and reach hundreds of thousands of passionate investors and traders? Reach us here.
Disclaimer: Content, news, research, tools, and securities symbols are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.
Reply